REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
851.73 MXN
67.15 B MXN
222.80 B MXN
105.94 M
About Regeneron Pharmaceuticals, Inc.
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Founded
1988
FIGI
BBG00JX0QK71
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
6.94%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.42%
Maturity date
Sep 15, 2030
Explore more bonds
Curated watchlists where REGN is featured.
Frequently Asked Questions
The current price of REGN is 15,576.00 MXN — it has increased by 2.87% in the past 24 hours. Watch REGENERON PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange REGENERON PHARMACEUTICALS INC stocks are traded under the ticker REGN.
REGN stock has fallen by −2.87% compared to the previous week, the month change is a −15.48% fall, over the last year REGENERON PHARMACEUTICALS INC has showed a −4.38% decrease.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC future price: according to them, REGN price has a max estimate of 25,060.10 MXN and a min estimate of 16,299.25 MXN. Watch REGN chart and read a more detailed REGENERON PHARMACEUTICALS INC stock forecast: see what analysts think of REGENERON PHARMACEUTICALS INC and suggest that you do with its stocks.
REGN stock is 3.19% volatile and has beta coefficient of 0.77. Track REGENERON PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS INC there?
Today REGENERON PHARMACEUTICALS INC has the market capitalization of 1.71 T, it has decreased by −1.27% over the last week.
Yes, you can track REGENERON PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMACEUTICALS INC is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 245.51 MXN per share, whereas the estimation was 230.43 MXN resulting in a 6.54% surprise. The estimated earnings for the next quarter are 229.14 MXN per share. See more details about REGENERON PHARMACEUTICALS INC earnings.
REGENERON PHARMACEUTICALS INC revenue for the last quarter amounts to 73.31 B MXN, despite the estimated figure of 72.41 B MXN. In the next quarter, revenue is expected to reach 77.50 B MXN.
REGN net income for the last quarter is 26.41 B MXN, while the quarter before that showed 26.27 B MXN of net income which accounts for 0.55% change. Track more REGENERON PHARMACEUTICALS INC financial stats to get the full picture.
No, REGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 13.45 K employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC EBITDA is 90.79 B MXN, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMACEUTICALS INC financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMACEUTICALS INC stock shows the strong sell signal. See more of REGENERON PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.